<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195894</url>
  </required_header>
  <id_info>
    <org_study_id>KC102-001/KC102-002</org_study_id>
    <nct_id>NCT03195894</nct_id>
  </id_info>
  <brief_title>Clinical Study of TripleA for Treatment of Alcohol Addiction in Outpatient Care</brief_title>
  <official_title>Clinical Study of TripleA Connected to Diagnosis, Care and Aftercare of Alcohol Addiction in Outpatient Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kontigo Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kontigo Care AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to investigate differences in the alcohol consumption pattern
      between alcohol addicts receiving conventional treatment and those who receive a combination
      of conventional treatment and TripleA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2015</start_date>
  <completion_date type="Actual">March 1, 2018</completion_date>
  <primary_completion_date type="Actual">February 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, controlled, open study to compare conventional treatment with and without addition of TripleA</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in heavy alcohol drinking days</measure>
    <time_frame>The four weeks-period before the 12 months visit</time_frame>
    <description>Difference in number of heavy alcohol drinking Days between the treatment arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in number of sober patients</measure>
    <time_frame>The four weeks-period before the 6 months visit</time_frame>
    <description>Difference in number of sober patients between the treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in number of sober patients</measure>
    <time_frame>The four weeks-period before the 12 months visit</time_frame>
    <description>Difference in number of sober patients between the treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in total amount of consumed alcohol</measure>
    <time_frame>The four weeks-period before the 6 months visit</time_frame>
    <description>Difference in total amount of consumed alcohol compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in total amount of consumed alcohol</measure>
    <time_frame>The four weeks-period before the 12 months visit</time_frame>
    <description>Difference in total amount of consumed alcohol compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in heavy alcohol drinking days</measure>
    <time_frame>The four weeks-period before the 6 months visit</time_frame>
    <description>Difference in heavy alcohol drinking days compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in heavy alcohol drinking days</measure>
    <time_frame>The four weeks-period before the 12 months visit</time_frame>
    <description>Difference in heavy alcohol drinking days compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in alcohol-free days</measure>
    <time_frame>The four weeks-period before the 6 months visit</time_frame>
    <description>Difference in alcohol-free days compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in alcohol-free days</measure>
    <time_frame>The four weeks-period before the 12 months visit</time_frame>
    <description>Difference in alcohol-free days compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in number of standard glasses</measure>
    <time_frame>The four weeks-period before the 6 months visit</time_frame>
    <description>Difference in number of standard glasses compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in number of standard glasses</measure>
    <time_frame>The four weeks-period before the 12 months visit</time_frame>
    <description>Difference in number of standard glasses compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>From date of randomization until the date of first relapse of drinking alcohol, assessed up to 12 months</time_frame>
    <description>Time period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Clinical Global Impression</measure>
    <time_frame>After 6 months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Clinical Global Impression</measure>
    <time_frame>After 12 months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health</measure>
    <time_frame>After 12 months</time_frame>
    <description>Measured by EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with lowered AUDIT score</measure>
    <time_frame>After 12 months</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with lowered AUDIT score with at least one zone</measure>
    <time_frame>After 12 months</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a risk level II</measure>
    <time_frame>After 12 months</time_frame>
    <description>Less than 6 AUDIT points for women and 8 AUDIT points for men</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of alcohol addiction</measure>
    <time_frame>After 6 months</time_frame>
    <description>Measured as the difference in SADD points compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of alcohol addiction</measure>
    <time_frame>After 12 months</time_frame>
    <description>Measured as the difference in SADD points compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>After 6 months</time_frame>
    <description>Change in blood concentrations of the alcohol metabolitesPEth and CDT compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>After 12 months</time_frame>
    <description>Change in blood concentrations of the alcohol metabolitesPEth and CDT compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Conventional treatment and TripleA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment and TripleA medical device consisting of alcoholometer, a Bluetooth mobile app on cell phone and information stored on computer for caregiver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TripleA</intervention_name>
    <arm_group_label>Conventional treatment and TripleA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in care at Addiction and Neuropsychiatry Uppsala University Hospital and at
             N채mndemansg책rden, J채lla, Uppsala

          -  18 years or older

          -  Meets at least 2 of the criteria for addiction/substance syndrome according to
             Diagnostic and statistical manual of mental disorders-5 (DSM-5)

          -  Ability to understand and communicate in Swedish

          -  Ability to handle the technical equipment used in the study (alcoholometer and
             Smartphone)

          -  Access to a fixed place (living, place for sleeping, place where the phone can be
             charged

        Exclusion Criteria:

          -  Schizophrenia

          -  Substance syndrome related to other substances than alcohol and nicotin

          -  Lowered lung function (not able to reach acceptable expiration volume for the
             alcoholometer function)

          -  The patient is taken care of within the frame for Lagen om V책rd av Missbrukare, LVM
             (Care of addicts regulations)

          -  Not suitable to participate according to the Investigator

          -  Has not consumed any alcohol during the 4 weeks defined as baseline timeline follow
             back

          -  Normalized Carbohydrate Deficient Transferrin (CDT) and Phosphatidyl-Ethanol
             (PEth)-values in blood samples at visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Eriksson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol abuse, Alcoholometer, Medical Device, App</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

